PBE

Invesco Dynamic Biotechnology & Genome ETF

Up$53.88
+$0.25
(+0.47%)
As of 8:00:00 PM EDT | 3/25/19  |  Market Closed

PBE Trading Data

Open

$53.55

Low Price

$53.26

High Price

$54.04

Previous Last Price

$53.63

Bid Size

$0 X 0

Ask Size

$0 X 0

PBE Portfolio Data

AUM

$273,258,000

Shares

5,100

PE Ratio

68.98

Price / Book Ratio

6.1

Expense Ratio

0.59

Net Asset Value

$53.58

Volume

Volume

8,500

Avg. Volume (YDT)

21,642

Dollar Volume

$399,476

Weekly Avg. Volume

9,800

Monthly Avg. Volume

9,440

Quarterly Avg. Volume

22,693

PBE Fund Description

The Invesco Dynamic Biotechnology and Genome ETF is based on the Dynamic Biotech and Genome Intellidex Index. The Fund will normally invest at least 90% of its total assets in common stocks that comprise the Index. The Intellidex Index is designed to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value. The Underlying Intellidex Index is comprised of common stocks of 30 US biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research. The Fund and the Index are rebalanced and reconstituted quarterly in February, May, August and November.

PBE Chart

PBE Summary

Fund Family

Invesco

Tracks This Index

Invesco Dynamic Biotechnology & Genome ETF

Inception Date

2005-06-23

Asset Class

Equity

Asset Class Size

Biotech

PBE Classification

Region (General)

North America

Region (Specific)

US

Sector

Health Care

Equity Index

Leveraged Family

PBE Holdings

Top 10 Holdings

Alnylam Pharmaceuticals Inc (ALNY)
5.68%
Illumina Inc (ILMN)
5.13%
QIAGEN NV (QGEN)
4.96%
Amgen Inc (AMGN)
4.93%
Celgene Corp (CELG)
4.82%
Vertex Pharmaceuticals Inc (VRTX)
4.76%
Regeneron Pharmaceuticals Inc (REGN)
4.59%
REGENXBIO Inc (RGNX)
3.56%
Akebia Therapeutics Inc (AKBA)
3.49%
Biogen Inc (BIIB)
3.37%

Total PBE Holdings

Total Holdings: 31

Alnylam Pharmaceuticals Inc (ALNY)
5.68%
Illumina Inc (ILMN)
5.13%
QIAGEN NV (QGEN)
4.96%
Amgen Inc (AMGN)
4.93%
Celgene Corp (CELG)
4.82%
Vertex Pharmaceuticals Inc (VRTX)
4.76%
Regeneron Pharmaceuticals Inc (REGN)
4.59%
REGENXBIO Inc (RGNX)
3.56%
Akebia Therapeutics Inc (AKBA)
3.49%
Biogen Inc (BIIB)
3.37%
Veracyte Inc (VCYT)
3.34%
PTC Therapeutics Inc (PTCT)
3.27%
Cardiovascular Systems Inc (CSII)
3.02%
Sangamo Therapeutics Inc (SGMO)
2.98%
Exelixis Inc (EXEL)
2.98%
Alkermes PLC (ALKS)
2.79%
Repligen Corp (RGEN)
2.77%
Arrowhead Pharmaceuticals Inc (ARWR)
2.75%
Myriad Genetics Inc (MYGN)
2.75%
Array BioPharma Inc (ARRY)
2.75%
United Therapeutics Corp (UTHR)
2.73%
Bio-Techne Corp (TECH)
2.69%
Enanta Pharmaceuticals Inc (ENTA)
2.64%
Catalent Inc (CTLT)
2.64%
FibroGen Inc (FGEN)
2.59%
Halozyme Therapeutics Inc (HALO)
2.58%
OPKO Health Inc (OPK)
2.58%
Genomic Health Inc (GHDX)
2.48%
Vanda Pharmaceuticals Inc (VNDA)
2.39%
Emergent BioSolutions Inc (EBS)
2%
PowerShares Dynamic Biotechnology & Genome Portfolio (PBE)
0%

PBE Technicals

Alpha

-9.01

Beta

1.42

Leverage

Long

Standard Deviation

4.12

PBE Dividends

Dividend Date

2018-09-24

Latest Dividend

0.002

Annual Dividend

0

Annual Dividend Rate

0

Annual Dividend Yield

1.0E-5

PBE Performance

YTD Return

14.47%

1 Year Return

9.43%

3 Year Return

37.25%

5 Year Return

35.11%

10 Year Return

324.27%

PBE Related Articles